Senior Director of Drug Safety

Ailux is an innovative biotechnology company focused on discovering and developing next-generation biologic and peptide therapeutics for chronic respiratory and immunological diseases with high unmet medical need. The company integrates advanced computational approaches with rigorous experimental and translational science across the drug discovery continuum, enabling faster and more informed decision-making from target identification through clinical candidate selection.

As an AI-native biotech and wholly owned subsidiary of Xtal Pi, Ailux combines proprietary computational models with state-of-the-art wet lab capabilities to design differentiated therapeutics against challenging biological targets. The company has established strategic partnerships with leading pharmaceutical organisations, providing external validation of its scientific platform and discovery capabilities. Looking ahead, Ailux’s vision is to build a fully integrated, end-to-end drug discovery and development organisation capable of delivering the next generation of medicines for patients with chronic respiratory and immunological diseases.

By combining advanced AI capabilities with deep biological, translational and clinical insight, the company aims to accelerate the development of differentiated therapeutics with meaningful impact for patients worldwide.

Backed by an experienced leadership team, leading scientific advisors and a highly multidisciplinary organisation, Ailux is approaching a key inflection point as its first wave of therapeutic programmes advances toward clinical development. This is an opportunity to help shape the scientific foundations, pipeline and culture of a rapidly growing biotechnology company operating at the intersection of AI, translational science and next-generation therapeutics.

We are seeking an experienced and strategic Senior Director of Drug Safety to establish and lead Ailux’s translational safety sciences capability across its respiratory and immunology pipeline. Reporting to the VP, Head of In Vivo Bioscience, the role will shape nonclinical and translational safety strategies supporting the progression of novel biologics, multi-specific antibodies and peptide therapeutics from discovery through early clinical development.

Working at the interface of computational design, translational biology and preclinical development, you will integrate mechanistic toxicology, pharmacology, DMPK and emerging clinical insights to enable informed, data-driven programme decisions and successful human translation.

The role offers the opportunity to shape translational safety strategy across a next-generation respiratory and immunology pipeline spanning biologics, multi-specifics and peptide therapeutics.

• Lead the nonclinical safety strategy across Ailux’s pipeline
• Shape candidate selection and go/no-go decisions through integrated mechanistic and translational safety assessment, balancing target biology, therapeutic index, exposure margins and clinical risk.
• Partner closely with DMPK, bioscience, translational and clinical teams to integrate PK/PD, exposure-response and safety data into human dose prediction and first-in-human strategy
• Partner with Platform Science teams to evaluate and optimise emerging technologies.

• Design and oversee nonclinical safety strategies supporting discovery through IND-enabling development for biologics, multi-specific antibodies and peptide therapeutics
• Provide strategic oversight across general toxicology, safety pharmacology, DART (developmental and reproductive toxicology), genotoxicity and investigative toxicology activities
• Integrate toxicology, pharmacology, DMPK, biomarker and…